Algernon Pharmaceuticals Inc. C.AGN

Alternate Symbol(s): AGNPF

Algernon Pharmaceuticals Inc. is a clinical-stage drug development company. The Company is focused on developing repurposed therapeutic drugs in the areas of non-alcoholic steatohepatitis (NASH), a type of liver disease, chronic kidney disease (CKD), inflammatory bowel disease (IBD), idiopathic pulmonary fibrosis (IPF) and chronic cough as well as advancing a stroke program using N, N-Dimethyltryptamine (DMT). The Company operates through two segments, which includes the development of repurposed therapeutic drugs in Canada and the facilitation of the Company’s lead drug candidates into off-label phase II clinical trials (humans) in Australia. The Company's pipeline includes NP-251 (Repirinast) and AP-188 (DMT). The Company, through its subsidiary, Algernon NeuroScience Inc., is developing AP-188 (DMT) as a potential treatment for stroke and traumatic brain injury (TBI) recovery. Its NP-251 is being developed as a potential treatment for kidney inflammation and fibrosis.

CSE:AGN - Post by User

Algernon Pharmaceuticals Inc. > Can someone please call the CEO this weekend and ask why?

<< Previous

Bullboard Posts

Next >>

Comment by rico91on Mar 20, 2021 10:19am

147 Views

Post# 32844700

RE:Can someone please call the CEO this weekend and ask why?

Great Idea!

Is your phone not working?

We are about 1 week away from the Data that we have all been waiting for. I really do not understand why you are worried about faces on the web site at this point in time?
If the results are good , I really don't care if their faces are there or not. I'm happy !
If the results are not good, I'm gone and guess what! I still would not care if the faces are there or not!
Waiting patiently and not worried about faces.
Rico

<< Previous

Bullboard Posts

Next >>

Paramount Resources signs $3.32 billion asset sale